secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-021110
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Therapeutics reports Q1 2024 results, FDA approval of Libervant, and progress on Anaphylm
--------------------------------------------------------------------------------

- Met all endpoints in Phase 3 pivotal study for Anaphylm (epinephrine) Sublingual Film compared to EpiPen and other injectors.
- Received FDA approval for Libervant (diazepam) Buccal Film in patients ages 2-5, now available in multiple strengths.
- Completed $77.5M underwritten public offering with institutional investors, extending cash runway into 2026.
- Total revenues increased to $12.1M in Q1 2024 from $11.1M in Q1 2023; net loss was $12.8M.
- On track to file Anaphylm NDA with FDA by end of 2024, with remaining studies expected by Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/aqst-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer